An Irish scientist has won an international award for helping to develop a malaria vaccine
Dublin-born scientist Adrian Hill was awarded the European Inventor Award in the research category from the European Patent Office in Berlin on Thursday
Hill and his team developed a vaccine that presents more of the malaria-specific protein regions needed to trigger a strong immune response, with around 75-80 per cent protection in clinical trials, exceeding the World Health Organisation’s (WHO) target for malaria vaccines
Advertisement
Hill studied medicine at Trinity College Dublin before completing a DPhil in human genetics at Oxford. He also helped develop the Oxford-AstraZeneca Covid-19 vaccine
According to WHO, there were an estimated 282 million malaria cases and 610,000 malaria deaths worldwide in 2024, with children under five accounting for around 75 per cent of malaria deaths in the WHO Africa region
Traditional malaria vaccines achieved only modest protection, particularly in young children
Hill and his team developed a vaccine that presents more of the malaria-specific protein regions needed to trigger a strong immune response
Advertisement
“I am delighted to accept this prestigious award on behalf of the many hundreds of people who have contributed to the discovery, development and licensure of our malaria vaccine over the past 12 years,” Hill said
Scientists have been attempting to develop a malaria vaccine for more than a century, but more than 150 vaccine candidates entered human trials before two finally succeeded
Hill’s team redesigned the vaccine structure to include more of the key malaria protein segments recognised by the immune system, while removing components that could divert the immune response
The vaccine can be produced at large scale, costs less than €3 per dose and remains stable for up to two years under standard refrigeration conditions, helping make vaccination programmes more accessible in regions where malaria remains endemic
Hill’s long-term commitment to malaria research was shaped by his 1988 experience in The Gambia, where he witnessed the impact of the disease on young children
Over the following three decades, his team at Oxford’s Jenner Institute investigated multiple vaccine candidates before developing R21/Matrix-M, the official name of the vaccine
Ghana became the first country to approve the vaccine in 2023, followed by Nigeria
Later that year, the WHO formally recommended R21/Matrix-M for widespread use
Malaria vaccination is now being integrated into routine immunisation programmes in more than 20 African countries, providing a new tool to reduce malaria-related illness and deaths
